Home

White Paper

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Medidata
Pages 13 Pages

Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood cytokine storm driven inflammatory disorder.Interleukin-6(IL-6) is a known disease driver in some patients, but anti-IL-6 therapy with siltux-imabis not effective in all patients, and biomarkers indicating success at an early time point following treatment initiation are lacking.

Join for free to read

You Might Also Like


The Path to Acceleration: In Silico Modeling Launches New Wave of Rare Disease Drug Development
White Paper The Path to Acceleration: In Silico Modeling Launches New Wave…
Premier Research

2023 rare disease study
Report 2023 rare disease study
Definitive Healthcare

2021 rare disease study
Report 2021 rare disease study
Definitive Healthcare

Neurodegenerative Disease Research
Case Study Neurodegenerative Disease Research
PerkinElmer

More from Medidata


A Review of the Changing Trends and Use of eCOA in Clinical Trials
White Paper A Review of the Changing Trends and Use of eCOA in Clinical…
Medidata

An interpretable data augmentation framework for improving generative modeling of synthetic clinical trial data
White Paper An interpretable data augmentation framework for improving…
Medidata

Better Data, Better Decisions
White Paper Better Data, Better Decisions
Medidata

Integrating and streamlining complex processes to better clinical trials
White Paper Integrating and streamlining complex processes to better…
Medidata
© 2025 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info